Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017636 (
glioblastoma
)
18,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glial tumors exhibit a high morbidity and mortality because of their invasive nature. Matrix metalloproteinase 19 (MMP19) is a secreted protease that together with
epilysin
(MMP28) forms a structural subgroup of MMPs. We analyzed their expression by quantitative reverse transcription polymerase chain reaction, Western blot, and immunohistochemistry in tumor and normal control brain tissues and in
glioblastoma
(GB) cells and performed MMP19 silencing functional assays. Matrix metalloproteinase 28 was transcribed to the same extent in normal brain samples and gliomas but was undetectable in GB cell lines. In contrast, MMP19 was detected by immunohistochemistry in normal brain samples only in endothelial cells but was found at high levels in astrocytomas of different World Health Organization grades in situ and in GB cells in vitro. Matrix metalloproteinase 19 was upregulated in GB cells after exposure to proinflammatory cytokines. In Transwell invasion assays, MMP19-silenced cells migrated more slowly through laminin-, basal lamina-, and brevican-coated membranes than controls. Matrix metalloproteinase 19-silenced GB cells also migrated into brain tissue slices compared with control cells. Brevican, a brain-specific proteoglycan and major component of brain extracellular matrix, was degraded by recombinant human MMP19. Taken together, these results indicate that MMP19 is highly expressed in proliferating astrocytoma/glioma cells, and that its expression may facilitate their invasion through brain extracellular matrix components.
...
PMID:Matrix metalloproteinase-19 is highly expressed in astroglial tumors and promotes invasion of glioma cells. 2014 69
As the newest identified member of the matrix metalloproteinase (MMP) family, the expression pattern and function of
epilysin
(MMP-28) are still not well understood. Although
epilysin
was found to play an evolutionarily conserved role in neural development, the expression and function of
epilysin
in malignant glioma are unknown. Therefore, the aim of the present study was to quantitatively evaluate the expression level of
epilysin
in
glioblastoma
(
GBM
) and its association with clinical outcome of patients. For this purpose, a total of 216
GBM
specimens and 31 normal brain specimens were collected in the present study. Expression level of
epilysin
was determined by immunohistochemistry assay and immunoreactivity score system. MGMT promoter methylation and IDH1/2 mutation status in
GBM
were also evaluated. Results showed that the positive rate of
epilysin
staining in
GBM
was significantly elevated compared with that in normal brain. Positive
epilysin
staining was associated with low KPS score, unmethylated MGMT promoter and wild-type IDH. Kaplan-Meier analysis showed that patients with
GBM
of positive
epilysin
staining were more likely to have unfavorable overall survival. Multivariate analysis revealed that
epilysin
was an independent and significant prognostic marker of
GBM
. These results proved for the first time that
epilysin
expression was significantly elevated in
GBM
and can be potentially used to predict prognosis in patients with
GBM
.
...
PMID:Epilysin is overexpressed in glioblastoma and related to clinical outcome of patients. 2542 35